![Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial - Journal of the American Academy of Dermatology Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial - Journal of the American Academy of Dermatology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/3ae0776c-72b8-4746-afdb-595b0cf33db5/gr4_lrg.jpg)
Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial - Journal of the American Academy of Dermatology
![Development and validation of the Physician's Global Assessment of Fingernail Psoriasis - Hudgens - 2021 - Journal of the European Academy of Dermatology and Venereology - Wiley Online Library Development and validation of the Physician's Global Assessment of Fingernail Psoriasis - Hudgens - 2021 - Journal of the European Academy of Dermatology and Venereology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/6aa214ca-782b-47f4-8bda-df7304a6921d/jdv17387-tbl-0002-m.jpg)
Development and validation of the Physician's Global Assessment of Fingernail Psoriasis - Hudgens - 2021 - Journal of the European Academy of Dermatology and Venereology - Wiley Online Library
![Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial - ScienceDirect Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0190962217322624-gr3.jpg)
Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial - ScienceDirect
![Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial - ScienceDirect Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0190962217322624-gr2.jpg)
Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial - ScienceDirect
![Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial - ScienceDirect Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0190962217322624-gr5.jpg)
Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial - ScienceDirect
![The state of the art—psoriatic arthritis outcome assessment in clinical trials and daily practice - The Lancet Rheumatology The state of the art—psoriatic arthritis outcome assessment in clinical trials and daily practice - The Lancet Rheumatology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/eadc8199-9366-4580-b937-289c4d2d9003/gr1_lrg.jpg)
The state of the art—psoriatic arthritis outcome assessment in clinical trials and daily practice - The Lancet Rheumatology
![The North Face ULTRA TR II and ULTRA CARDIAC shoes new for 2015 | iancorless.com - Photography, Writing, Talk Ultra Podcast The North Face ULTRA TR II and ULTRA CARDIAC shoes new for 2015 | iancorless.com - Photography, Writing, Talk Ultra Podcast](https://talkultra.files.wordpress.com/2015/02/the-north-face-logo.jpg)
The North Face ULTRA TR II and ULTRA CARDIAC shoes new for 2015 | iancorless.com - Photography, Writing, Talk Ultra Podcast
![Narrative Review of the Emerging Therapeutic Role of Brodalumab in Difficult-to-Treat Psoriasis | SpringerLink Narrative Review of the Emerging Therapeutic Role of Brodalumab in Difficult-to-Treat Psoriasis | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs13555-022-00746-6/MediaObjects/13555_2022_746_Fig2_HTML.png)
Narrative Review of the Emerging Therapeutic Role of Brodalumab in Difficult-to-Treat Psoriasis | SpringerLink
![Narrative Review of the Emerging Therapeutic Role of Brodalumab in Difficult-to-Treat Psoriasis | SpringerLink Narrative Review of the Emerging Therapeutic Role of Brodalumab in Difficult-to-Treat Psoriasis | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs13555-022-00746-6/MediaObjects/13555_2022_746_Fig3_HTML.png)